BeiGene, Ltd. (ONC)vsQuantum BioPharma Ltd. (QNTM)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
QNTM
Quantum BioPharma Ltd.
$4.73
+52.58%
HEALTHCARE · Cap: $11.91M
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
QNTM
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for QNTM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : QNTM
The strongest argument for QNTM centers on Debt/Equity, Price/Book.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : QNTM
The primary concerns for QNTM are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while QNTM is a value play — different risk/reward profiles.
QNTM carries more volatility with a beta of 0.60 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 26/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Quantum BioPharma Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on developing groundbreaking therapies for complex medical conditions, particularly in underserved areas such as oncology and autoimmune disorders. With a robust pipeline of advanced biopharmaceutical products, the company leverages cutting-edge technologies and a commitment to rigorous research and development. Quantum BioPharma’s strategic partnerships and a seasoned leadership team enhance its potential to capitalize on the growing demand for novel therapeutics, positioning it as a compelling investment opportunity within the dynamic biopharmaceutical landscape.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?